<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Med Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Eur. J. Med. Res</journal-id>
      <journal-title-group>
        <journal-title>European Journal of Medical Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0949-2321</issn>
      <issn pub-type="epub">2047-783X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25262004</article-id>
      <article-id pub-id-type="pmc">4189628</article-id>
      <article-id pub-id-type="publisher-id">51</article-id>
      <article-id pub-id-type="doi">10.1186/s40001-014-0051-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Diagnosis and treatment of a 16-year-old Chinese patient with concurrent hereditary hemochromatosis and Gilbert's syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Wang</surname>
            <given-names>Xianbo</given-names>
          </name>
          <address>
            <email>Wangxianbo022714@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Yanmin</given-names>
          </name>
          <address>
            <email>lym5271986@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Yujuan</given-names>
          </name>
          <address>
            <email>changyujuanyi@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Huimin</given-names>
          </name>
          <address>
            <email>lhm1205@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Wang</surname>
            <given-names>Peng</given-names>
          </name>
          <address>
            <email>chinaroc@tom.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015 China </aff>
        <aff id="Aff2"><label/>Department of Pathology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015 China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>19</volume>
      <issue>1</issue>
      <elocation-id>51</elocation-id>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Wang et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Gilbert&#x2019;s syndrome and hereditary hemochromatosis predominantly affect Caucasians with a low incidence in Asians. Here we report the case of a 16-year-old Chinese boy, who was admitted with hepatalgia, jaundice, hyperpigmentation, and splenomegaly to our hospital. After excluding chronic hepatitis, autoimmune disorders, and alcohol or drug injury, genetic analyses of the patient and his parents revealed simultaneous manifestations of Gilbert&#x2019;s syndrome and hereditary hemochromatosis, though his parents did not develop related symptoms. The presented case indicates that diagnoses of Gilbert&#x2019;s syndrome and hereditary hemochromatosis should be taken into consideration when chronic hepatitis is suspected without a clear etiology.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Hereditary hemochromatosis</kwd>
        <kwd>Gilbert&#x2019;s syndrome</kwd>
        <kwd>Liver biopsy</kwd>
        <kwd>Mutation</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Hereditary hemochromatosis (HHC) is an autosomal recessive genetic disorder caused by mutations in the high iron Fe (<italic>HFE</italic>) gene, which leads to exacerbated iron uptake and storage [<xref ref-type="bibr" rid="CR1">1</xref>]. Gilbert&#x2019;s syndrome (GS) is an autosomal inherited disease that manifests as intermittent unconjugated hyperbilirubinemia. It is caused by mutations of the UDP-glucuronosyltransferase1A1 (<italic>UGT1A1</italic>) gene, which has the function of rendering bilirubin water soluble via glucuronidation [<xref ref-type="bibr" rid="CR2">2</xref>]. Because of the low HHC prevalence in Asians [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>] and the high rate of GS unawareness [<xref ref-type="bibr" rid="CR5">5</xref>], adolescent HHC concurrent with GS cases are rarely found in China.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 16-year-old boy was admitted to our hospital with a 1-year history of repeated epigastric pain and 6&#xA0;months mild jaundice. We found skin hyperpigmentation, liver tenderness, splenomegaly, and mild jaundice of the skin and sclera during physical examination, while the first onset of skin hyperpigmentation occurred 3&#xA0;years ago. We first presumed that he might have developed chronic hepatitis, caused by virus infections, drug or alcohol abuse, or autoimmune/metabolic disorders. Laboratory tests revealed 61.8&#xA0;&#x3BC;mol/L total bilirubin (TBIL) (normal range, 0 to 18.8&#xA0;&#x3BC;mol/L) and 7.5&#xA0;&#x3BC;mol/L direct bilirubin (DBIL) (normal range, 0 to 6.8&#xA0;&#x3BC;mol/L) concentrations, pointing to Gilbert&#x2019;s syndrome. Iron metabolism analyses indicated abnormal serum concentrations of iron (39.42&#xA0;&#x3BC;mol/L; normal range, 9.5 to 29.9&#xA0;&#x3BC;mol/L), ferritin (410.02&#xA0;ng/mL; normal range, 21.81 to 274.66&#xA0;ng/mL) and transferrin (187.00&#xA0;mg/dl; normal range, 200 to 400&#xA0;mg/dl) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Other serological parameters were normal (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). An abdominal ultrasound examination revealed diffused liver lesions and splenomegaly (28&#xA0;mm below the costal margin) but no abnormalities in the extrahepatic bile ducts or pancreas. Negative hepatitis serology, autoimmune antibody, and copper-protein results meant that viral hepatitis, autoimmune hepatitis, and Wilson&#x2019;s disease could be excluded from the diagnosis. Because the patient did not consume alcohol or take drugs, did not receive blood transfusions or iron-supplementary nutrition, or ingest hepatotoxic drugs or chalybeate (natural mineral springs containing iron salts), we could also exclude secondary hemochromatosis, alcoholic hepatitis, and drug-induced hepatitis. In order to clarify the cause of the liver injury, a liver biopsy was carried out and the results revealed lipofuscin sedimentation in hepatocytes in zone 1 of the hepatic acinus (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>A,B) as well as excessive iron in acinar zone 3 hepatocytes around the central vein (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>C,D). The histopathological findings made us take a diagnosis of hereditary hemochromatosis (HHC) into consideration, though his family did not have a history of obvious HHC or disorders of iron metabolism. Gene analysis (SeqMan DNA Star 6.0 software, Lasergene, Madison, WI, USA) after amplifications with specific primers (Applied Biosystems, Carlsbad, CA, USA) revealed a heterozygous H63D and a homozygous IVS 2&#x2009;+&#x2009;4&#xA0;T&#x2009;&#x2192;&#x2009;C mutation in <italic>HFE</italic> as well as a heterozygous G71R mutation in the <italic>UGT1A1</italic> gene, confirming the diagnosis of HFE-related HHC and concurrent GS. After the definite diagnosis, the patient was discharged and a 300&#xA0;mL therapeutic phlebotomy performed each week. However, after 9&#xA0;weeks, the TBIL, iron, and ferritin serum levels of the patient were slightly enhanced (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). We adjusted the bloodletting protocol to 400&#xA0;mL per week and urged the patient to attend the clinic for phlebotomies more regularly. After 9&#xA0;weeks, the relevant serum concentrations were decreased significantly and 4&#xA0;weeks later, the TBIL and iron levels were reduced further (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>), with the patient&#x2019;s symptoms being obviously relieved.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>The baseline characteristics of the patient</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Laboratory parameters</bold>
</th><th>
<bold>Results</bold>
</th><th>
<bold>Normal range</bold>
</th></tr></thead><tbody><tr valign="top"><td>Iron (&#x3BC;mol/L)</td><td>39.42</td><td>9.5-29.9</td></tr><tr valign="top"><td>Transferrin (mg/dL)</td><td>187</td><td>200-400</td></tr><tr valign="top"><td>Ferritin (ng/mL)</td><td>410.02</td><td>21.81-274.66</td></tr><tr valign="top"><td>Alanine aminotransferase (ALT) (U/L)</td><td>8.4</td><td>9.00-50.00</td></tr><tr valign="top"><td>Aspartate aminotransferase (AST) (U/L)</td><td>15.1</td><td>15.00-40.00</td></tr><tr valign="top"><td>Total bilirubin (TBIL) (&#x3BC;mol/L)</td><td>61.8</td><td>0-18.80</td></tr><tr valign="top"><td>Direct bilirubin (DBIL) (&#x3BC;mol/L)</td><td>7.5</td><td>0-6.80</td></tr><tr valign="top"><td>Total protein (TP) (g/L)</td><td>76.9</td><td>65.00-85.00</td></tr><tr valign="top"><td>Albumen (ALB) (g/L)</td><td>49.4</td><td>40.00-55.00</td></tr><tr valign="top"><td>Globulin (Glo) (g/L)</td><td>27.5</td><td>20.00-40.00</td></tr><tr valign="top"><td>Gamma-glutamyl transferase (GGT) (U/L)</td><td>12.8</td><td>10.00-60.00</td></tr><tr valign="top"><td>Alkaline phosphatase (ALP) (U/L)</td><td>110.3</td><td>45.00-125.00</td></tr><tr valign="top"><td>Cholinesterase (CHE) (U/L)</td><td>6882</td><td>4000.00-11000.00</td></tr><tr valign="top"><td>Total bile acid (TBA) (&#x3BC;mol/L)</td><td>3.6</td><td>0-10.00</td></tr><tr valign="top"><td>Prothrombin activity (PTA) (%)</td><td>68.3</td><td>80-120</td></tr><tr valign="top"><td>White blood cell (WBC) (10<sup>9</sup>/L)</td><td>8.79</td><td>4.00-10.00</td></tr><tr valign="top"><td>Neutrophilic (%)</td><td>62.5</td><td>50.00-75.00</td></tr><tr valign="top"><td>Lymphocytes (%)</td><td>31.2</td><td>20.00-40.00</td></tr><tr valign="top"><td>Red blood cell (RBC) (10<sup>12</sup>/L)</td><td>3.71</td><td>4.00-5.50</td></tr><tr valign="top"><td>Hemoglobin (HB) (g/L)</td><td>133.4</td><td>120.00-160.00</td></tr><tr valign="top"><td>Platelet (PLT) (10<sup>9</sup>/L)</td><td>290</td><td>100.00-300.00</td></tr><tr valign="top"><td>Anti-nuclear antibody (ANA)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Anti-mitochondria antibody (AMA)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Anti-smooth muscle antibody (SMA)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Human anti-gastric parietal cell antibody (AGPA)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Human anti-myocardial antibody (HMA)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Human anti-liver-kidney microsomal antibody (LKM)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Human anti-mitochondrial antibody M2 subtype (AMA-M2)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Human anti-centromere antibody (ACA)</td><td>Negative</td><td>Negative</td></tr><tr valign="top"><td>Immunoglobulin G (g/L)</td><td>12.7</td><td>7.51-15.60</td></tr><tr valign="top"><td>Immunoglobulin A (g/L)</td><td>2.02</td><td>0.82-4.53</td></tr><tr valign="top"><td>Immunoglobulin M (g/L)</td><td>1.49</td><td>0.40-2.74</td></tr><tr valign="top"><td>Complement 3 (C3) (g/L)</td><td>0.53</td><td>0.79-1.52</td></tr><tr valign="top"><td>Complement 4 (C4 ) (g/L)</td><td>0.13</td><td>0.16-0.38</td></tr><tr valign="top"><td>Ceruloplasmin (g/L)</td><td>0.21</td><td>0.22-0.58</td></tr><tr valign="top"><td>Rheumatoid factor (RF) (IU/mL)</td><td>&lt;20</td><td>0-20.00</td></tr><tr valign="top"><td>&#x3B1;1-Globulin (g/L)</td><td>3.6</td><td>2.9-4.9</td></tr><tr valign="top"><td>&#x3B1;2-Globulin (g/L)</td><td>5.3</td><td>7.1-11.8</td></tr><tr valign="top"><td>&#x3B2;1-Globulin (g/L)</td><td>4.3</td><td>4.7-7.2</td></tr><tr valign="top"><td>&#x3B2;2-Globulin (g/L)</td><td>2.9</td><td>3.2-6.5</td></tr><tr valign="top"><td>&#x3B3;-Globulin (g/L)</td><td>16.6</td><td>11.1-18.8</td></tr><tr valign="top"><td>Hepatitis B surface antigens (HBsAg) (IU/mL)</td><td>Negative</td><td>&lt;0.05</td></tr><tr valign="top"><td>Anti-HCV (S/CO)</td><td>0.11</td><td>&lt;1</td></tr><tr valign="top"><td>Blood glucose (&#x3BC;mol/L)</td><td>5.09</td><td>4.16-6.44</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Hepatic biopsy tissues (A and B: hematoxylin-eosin staining showing lipofuscin sedimentation (arrows) in acinar zone 1 hepatocytes.</bold>
<bold>C</bold> and <bold>D</bold>: prussian blue staining showing iron deposits (arrows) in the peripheral hepatic cells of the central vein. Original magnification: A and C &#xD7;200; B and D, &#xD7;400).</p></caption><graphic xlink:href="40001_2014_51_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Changes of ferrokinetic parameters and bilirubin levels in the patient&#x2019;s serum during bloodletting therapy</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Follow-up</bold>
</th><th>
<bold>Bloodletting therapy</bold>
</th><th>
<bold>TBIL (&#x3BC;mol/L)</bold>
</th><th>
<bold>DBIL (&#x3BC;mol/L)</bold>
</th><th>
<bold>Serum iron (&#x3BC;mol/L)</bold>
</th><th>
<bold>Transferrin (mg/dL)</bold>
</th><th>
<bold>Ferritin (ng/mL)</bold>
</th></tr></thead><tbody><tr valign="top"><td>0</td><td>0</td><td>61.80</td><td>7.50</td><td>39.42</td><td>187.00</td><td>410.02</td></tr><tr valign="top"><td>1</td><td>300&#xA0;mL/week</td><td>105.60</td><td>9.80</td><td>40.07</td><td>155.00</td><td>424.19</td></tr><tr valign="top"><td>2</td><td>400&#xA0;mL/week</td><td>41.70</td><td>7.40</td><td>7.97</td><td>224.00</td><td>324.51</td></tr><tr valign="top"><td>3</td><td>400&#xA0;mL/week</td><td>37.20</td><td>7.60</td><td>8.42</td><td>234.00</td><td>333.68</td></tr></tbody></table></table-wrap></p>
      <p>The research was approved by the ethics committee of Beijing Ditan hospital, Capital Medical University.</p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>The low prevalence in China and non-specific symptoms can mean that the diagnosis of HHC might sometimes be overlooked. However, as the patient developed hyperferritinemia, we suspected hemochromatosis and since he had not previously had blood transfusions or ingested chalybeate, secondary hemochromatosis could be excluded. However, for a definite HHC diagnosis, genetic testing is necessary and we also genetically screened the patient&#x2019;s first-degree relatives. His mother was found to be a homozygous IVS 2&#x2009;+&#x2009;4&#xA0;T&#x2009;&#x2192;&#x2009;C and heterozygous <italic>UGT1A1</italic> G71R mutation carrier without symptoms. His father was homozygous for IVS 2&#x2009;+&#x2009;4&#xA0;T&#x2009;&#x2192;&#x2009;C and has a heterozygous H63D mutation. His <italic>UGT1A1</italic> gene contains a heterozygous G71R and an additional heterozygous Y486D mutation, which he did not pass over to his son.</p>
      <p>Some authors suggest that IVS 2&#x2009;+&#x2009;4&#xA0;T&#x2009;&#x2192;&#x2009;C might be involved in specific splice activity [<xref ref-type="bibr" rid="CR6">6</xref>] but no correlation with HHC or the incidence of iron overload could be detected [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>], which explains the lack of HHC symptoms in the patient&#x2019;s mother. In contrast to Caucasians, HHC is rare in Asians and mostly restricted to H63D mutations in the <italic>HFE</italic> gene [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>]. A H63D heterozygous mutation is not generally associated with a hemochromatosis phenotype unless it occurs as a C282Y-H63D compound heterozygosity, or additional exogenous factors are triggered. Although symptoms of obvious iron overload were absent in the father, his serum iron concentration of 33.44&#xA0;&#x3BC;mol/L was slightly elevated and the 198&#xA0;mg/dL transferrin value was close to the lower limit of the normal range.</p>
      <p>G71R is the most common single nucleotide polymorphism (SNP) of the <italic>UGT1A1</italic> gene in Asia. Hepatic glucuronidation activity in subjects with heterozygous G71R mutations were 60.2&#x2009;&#xB1;&#x2009;3.5% of the wild type activity, which was considered somewhat high for a subject to develop GS [<xref ref-type="bibr" rid="CR9">9</xref>] and is in accordance with the normal bilirubin serum concentration of the patient&#x2019;s mother. In contrast, Y486D SNP were reported to have stronger inhibitory effects on <italic>UGT1A1</italic> and most Asian GS patients belong to the compound G71R/Y486D mutation group [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref>]. The data of the patient&#x2019;s father are in line with these findings because his <italic>UGT1A1</italic> gene contains heterozygous G71R plus Y486D mutations with resulting enhanced bilirubin levels. Extraordinarily, our 16-year-old patient, who has only one heterozygous <italic>UGT1A1</italic> SNP (G71R), developed even higher TBIL and DBIL serum concentrations (Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Bilirubin levels and ferrokinetic parameters in the family</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>TBIL (&#x3BC;mol/L)</bold>
</th><th>
<bold>DBIL (&#x3BC;mol/L)</bold>
</th><th>
<bold>IBIL (&#x3BC;mol/L)</bold>
</th><th>
<bold>Serum iron (&#x3BC;mol/L)</bold>
</th><th>
<bold>Transferrin (mg/dL)</bold>
</th><th>
<bold>Ferritin (ng/mL)</bold>
</th></tr></thead><tbody><tr valign="top"><td>The patient</td><td>61.80</td><td>7.50</td><td>54.30</td><td>39.42</td><td>187.00</td><td>410.02</td></tr><tr valign="top"><td>His father</td><td>27.20</td><td>9.40</td><td>17.80</td><td>33.44</td><td>198.00</td><td>44.78</td></tr><tr valign="top"><td>His mother</td><td>14.80</td><td>3.00</td><td>11.80</td><td>13.27</td><td>246.42</td><td>91.80</td></tr></tbody></table><table-wrap-foot><p>Normal ranges: TBIL, 0-18.8&#xA0;&#x3BC;mol/L; DBIL, 0-6.8&#xA0;&#x3BC;mol/L; serum iron, 9.5-29.9&#xA0;&#x3BC;mol/L; transferrin, 200-400&#xA0;mg/dL; ferritin, 21.81-274.66&#xA0;ng/mL.</p></table-wrap-foot></table-wrap></p>
      <p><italic>HFE</italic> mutations alone do not automatically produce symptoms of iron overload. Iron stores and inflammation are inducers of hepcidin, which acts as negative regulator of iron absorption in the small intestine as well as iron release from macrophages [<xref ref-type="bibr" rid="CR12">12</xref>]. Impairment of hepcidin activity, which is principal regulator of systemic iron homeostasis, has been correlated with HFE-related hemochromatosis [<xref ref-type="bibr" rid="CR13">13</xref>]. Also, bilirubin levels are thought to influence the state of iron homeostasis. An earlier publication noted that 23% of HHC patients showed increased unconjugated bilirubin serum concentrations [<xref ref-type="bibr" rid="CR14">14</xref>]. Bilirubin is an antioxidant [<xref ref-type="bibr" rid="CR15">15</xref>] and iron causes oxidative stress [<xref ref-type="bibr" rid="CR16">16</xref>]; oxidative stress-induced hemeoxygenase-1 activity has been proposed to cause enhanced bilirubin serum concentrations in some <italic>HFE</italic> mutation carriers, which counteracts the high oxidative stress produced by excess iron and may thus contribute to reduced penetrance [<xref ref-type="bibr" rid="CR17">17</xref>]. The protective role of bilirubin in individuals with <italic>HFE</italic> mutations might be applicable to the patient&#x2019;s father, but based on observations of patients with HHC and simultaneous mutations of the <italic>UGT1A1</italic> gene, Romanowski <italic>et al.</italic> proposed that high levels of bilirubin might promote iron loading by decreasing oxidative stress, in addition to reduced hepcidin signaling due to less inflammatory processes [<xref ref-type="bibr" rid="CR18">18</xref>], which might explain the iron overload in the son. Notably, the son developed more pronounced enhancements of TBIL and IBIL serum concentrations compared to his father, even though he has one less mutation in his <italic>UGT1A1</italic> gene. We suggest that in this case, increased iron absorption lead to oxidative stress and induced heme oxygenase, resulting in an increase in serum bilirubin. The higher bilirubin levels led to higher iron storage tolerance and in turn triggered even more heme oxygenase activity. Finally, the balance between oxidative stress and antioxidant bilirubin production caused the pronounced elevated bilirubin and serum iron concentrations.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>In summary, our 16-year-old Chinese patient with hepatalgia, jaundice, hyperpigmentation, and splenomegaly was shown to be a heterozygous H63D and homozygous IVS 2&#x2009;+&#x2009;4&#xA0;T&#x2009;&#x2192;&#x2009;C <italic>HFE</italic> and heterozygous G71R <italic>UGT1A1</italic> gene mutation patient with simultaneous HHC and GS manifestations. Astonishingly his father, who had the same SNPs in both genes plus an additional heterozygous Y486D mutation in <italic>UGT1A1</italic>, was not affected.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient&#x2019;s parents for the publication of this report and any accompanying images.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>DBIL</term>
            <def>
              <p>Direct bilirubin</p>
            </def>
          </def-item>
          <def-item>
            <term>GS</term>
            <def>
              <p>Gilbert&#x2019;s syndrome</p>
            </def>
          </def-item>
          <def-item>
            <term>HHC</term>
            <def>
              <p>Hereditary hemochromatosis</p>
            </def>
          </def-item>
          <def-item>
            <term>IBIL</term>
            <def>
              <p>Indirect bilirubin</p>
            </def>
          </def-item>
          <def-item>
            <term>SNPs</term>
            <def>
              <p>Single nucleotide polymorphisms</p>
            </def>
          </def-item>
          <def-item>
            <term>TBIL</term>
            <def>
              <p>Total bilirubin</p>
            </def>
          </def-item>
          <def-item>
            <term>
              <italic>UGT1A1</italic>
            </term>
            <def>
              <p>UDP-glucuronosyltransferase 1A1</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>Xianbo Wang and Yanmin Liu contributed equally.</p>
      </fn>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>XW, YL, and PW were responsible for the conception and design of the study. XW, YL, YC, HL, and PW were responsible for the acquisition of data. XW, YL, and PW drafted the manuscript. All authors participated in interpretation of the findings. XW and PW revised and commented on the draft, and all authors read and approved the final version of the manuscript. All authors confirm that the content has not been published elsewhere and does not overlap with or duplicate their previously published work.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported by grants from the National Natural Science Fund (81273743), Beijing Technology Discipline Project (Z111107056811044), and the 215 Program from Beijing Municipal Health Bureau (2013-2-11).</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrews</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Molecular control of iron metabolism</article-title>
          <source>Best Pract Res Clin Haematol</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>159</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beha.2004.10.004</pub-id>
          <pub-id pub-id-type="pmid">15737882</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kadakol</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Sappal</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chowdhury</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Chowdhury</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype</article-title>
          <source>Hum Mutat</source>
          <year>2000</year>
          <volume>16</volume>
          <fpage>297</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="doi">10.1002/1098-1004(200010)16:4&lt;297::AID-HUMU2&gt;3.0.CO;2-Z</pub-id>
          <pub-id pub-id-type="pmid">11013440</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>HFE gene mutation, C282Y causing hereditary hemochromatosis in Caucasian is extremely rare in Korean population</article-title>
          <source>J Korean Medical Sci</source>
          <year>2000</year>
          <volume>15</volume>
          <fpage>179</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.3346/jkms.2000.15.2.179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanson</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Imperatore</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>HFE gene and hereditary hemochromatosis: a HuGE review</article-title>
          <source>Human Genome Epidemiology</source>
          <year>2001</year>
          <volume>154</volume>
          <fpage>193</fpage>
          <lpage>206</lpage>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Claridge</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Booth</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Gilbert&#x2019;s syndrome</article-title>
          <source>BMJ</source>
          <year>2011</year>
          <volume>342</volume>
          <fpage>d2293</fpage>
          <pub-id pub-id-type="doi">10.1136/bmj.d2293</pub-id>
          <pub-id pub-id-type="pmid">21508045</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikhailova</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Babenko</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Voevoda</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Romashchenko</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>The ethnospecific distribution of the HFE haplotypes for IVS2(+4)t/c, IVS4(-44)t/c, and IVS5(-47)g/a in populations of Russia and possible effects of these single-nucleotide polymorphisms in splicing</article-title>
          <source>Genet Test Mol Biomarkers</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>461</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="doi">10.1089/gtmb.2009.0203</pub-id>
          <pub-id pub-id-type="pmid">20642366</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curcio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fornaciari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mariotti</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Chelazzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scatena</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Presciuttini</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Haplotype analysis of the H63D, IVS2&#x2009;+&#x2009;4&#xA0;t/c, and C282Y polymorphisms of the HFE gene reveals rare events of intragenic recombination</article-title>
          <source>Eur J Haematol</source>
          <year>2008</year>
          <volume>80</volume>
          <fpage>341</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0609.2007.01025.x</pub-id>
          <pub-id pub-id-type="pmid">18182079</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Lucas</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Fulgencio</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Sierra</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>del Rey Cerros</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Is the IVS2&#x2009;+&#x2009;4&#xA0;T&#x2009;&gt;&#x2009;C variant of the HFE gene a splicing mutation or a polymorphism? A study in the Spanish population</article-title>
          <source>Genet Med</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>212</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1097/01.GIM.0000157125.89581.09</pub-id>
          <pub-id pub-id-type="pmid">15775762</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujiyama</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Doida</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Bamba</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert&#x2019;s syndrome and Crigler-Najjar syndrome type II</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1998</year>
          <volume>1406</volume>
          <fpage>267</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.1016/S0925-4439(98)00013-1</pub-id>
          <pub-id pub-id-type="pmid">9630669</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Udomuksorn</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Elliot</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Mackenzie</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Yoovathaworn</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miners</surname>
              <given-names>JO</given-names>
            </name>
          </person-group>
          <article-title>Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates</article-title>
          <source>Pharmacogenet Genomics</source>
          <year>2007</year>
          <volume>17</volume>
          <fpage>1017</fpage>
          <lpage>1029</lpage>
          <pub-id pub-id-type="doi">10.1097/FPC.0b013e328256b1b6</pub-id>
          <pub-id pub-id-type="pmid">18004206</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maruo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ozgenc</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mimura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ota</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Taga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Compound heterozygote of a novel missense mutation (p.K402T) and a double missense mutation (p.[G71R;Y486D]) in type II Crigler-Najjar syndrome</article-title>
          <source>J Pediatr Gastroenterol Nutr</source>
          <year>2011</year>
          <volume>52</volume>
          <fpage>362</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="doi">10.1097/MPG.0b013e3181fcafb8</pub-id>
          <pub-id pub-id-type="pmid">21297505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bennoun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devaux</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Beaumont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grandchamp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vaulont</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>8780</fpage>
          <lpage>8785</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.151179498</pub-id>
          <pub-id pub-id-type="pmid">11447267</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bridle</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Frazer</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Wilkins</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Dixon</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Purdie</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Subramaniam</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Ramm</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
          <article-title>Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <fpage>669</fpage>
          <lpage>673</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(03)12602-5</pub-id>
          <pub-id pub-id-type="pmid">12606179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>CQ</given-names>
            </name>
            <name>
              <surname>Cartwright</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Skolnick</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Amos</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Homozygosity for hemochromatosis: clinical manifestations</article-title>
          <source>Ann Intern Med</source>
          <year>1980</year>
          <volume>93</volume>
          <fpage>519</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-93-4-519</pub-id>
          <pub-id pub-id-type="pmid">7436183</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stocker</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>McDonagh</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Ames</surname>
              <given-names>BN</given-names>
            </name>
          </person-group>
          <article-title>Bilirubin is an antioxidant of possible physiological importance</article-title>
          <source>Science</source>
          <year>1987</year>
          <volume>235</volume>
          <fpage>1043</fpage>
          <lpage>1046</lpage>
          <pub-id pub-id-type="doi">10.1126/science.3029864</pub-id>
          <pub-id pub-id-type="pmid">3029864</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Videla</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tapia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Varela</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells</article-title>
          <source>Biometals</source>
          <year>2003</year>
          <volume>16</volume>
          <fpage>103</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1020707811707</pub-id>
          <pub-id pub-id-type="pmid">12572670</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alizadeh</surname>
              <given-names>BZ</given-names>
            </name>
            <name>
              <surname>Njajou</surname>
              <given-names>OT</given-names>
            </name>
            <name>
              <surname>Houwing-Duistermaat</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vergeer</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pols</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>van Duijn</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Does bilirubin protect against hemochromatosis gene (HFE) related mortality?</article-title>
          <source>Am Journal Medical Genetics Part A</source>
          <year>2004</year>
          <volume>129A</volume>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.30163</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Romanowski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sikorska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bielawski</surname>
              <given-names>KP</given-names>
            </name>
          </person-group>
          <article-title>UGT1A1 gene polymorphism as a potential factor inducing iron overload in the pathogenesis of type 1 hereditary hemochromatosis</article-title>
          <source>Hepatol Res</source>
          <year>2009</year>
          <volume>39</volume>
          <fpage>469</fpage>
          <lpage>478</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1872-034X.2008.00487.x</pub-id>
          <pub-id pub-id-type="pmid">19207584</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
